BofA analyst Michael Cherny raised the firm’s price target on GoHealth to $11 from $9.75 and keeps a Neutral rating on the shares. GoHealth’s Q4 results were mixed, largely due to the impact of lookback adjustments related to the timing of performance obligations that reduced revenue and EBITDA, the analyst tells investors in a research note. The firm still sees “significant uncertainty” around GoHealth’s profitability and intermediate growth.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GOCO:
Click Here to Read the Full Original Article at TipRanks Financial Blog…
